We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?
Read MoreHide Full Article
We expect Bristol-Myers Squibb Company (BMY - Free Report) to beat expectations when it reports third-quarter 2017 results on Oct 26, before the market opens.
Year to date, Bristol-Myers’ shares have increased 10.2% while the industry has recorded an increase of 20.5%.
Bristol-Myers’ track record has been positive so far. The company delivered positive earnings surprise in three of the last four quarters and missed expectations in one. The average positive earnings surprise in the last four quarters is 7.99%. In the last reported quarter, Bristol-Myers came up with a positive surprise of 1.37%.
Let’s see how things are shaping up for this quarter.
Factors at Play
Bristol-Myers’ high-profile immuno-oncology drug, Opdivo is expected to be the primary sales driver in the third quarter. The drug is already approved in multiple cancer indications. During this quarter, the FDA approved the drug for two additional indications – hepatocellular carcinoma and metastatic colorectal cancer – in patients who have received prior treatment. Although, these label expansions are not expected to have much impact on the top line, these when combined with the two label expansions in the second quarter will certainly boost sales.
Although the second quarter saw some stability in the second-line lung cancer setting, FDA’s approval of Merck’s (MRK - Free Report) Keytruda in May for the first-line treatment of metastatic nonsquamous NSCLC will increase competition and may impact sales unfavorably. The Zacks Consensus Estimates indicates the drug sales to increase 31% from the year-ago quarter to $1.2 billion.
In July, the FDA also approved the label expansion of Yervoy injection in pediatric patients 12 years of age and older with unresectable or metastatic melanoma. The Zacks Consensus Estimate for the drug this quarter is $323 million.
Meanwhile, rheumatoid arthritis drug, Orencia, received approval for treating psoriatic arthritis in the United States as well as in Europe in July. Moreover, in June, Bristol-Myers announced the availability of subcutaneous administration option for Orencia in patients with moderately to severely active polyarticular juvenile idiopathic arthritis. The label expansion and new administration option is expected to fuel growth of the drug. The drug, which registered growth of 10% in the previous quarter, is expected to generate sales of $635 million this quarter, per the Zacks Consensus Estimate.
On the other hand, the decline in the Hepatitis C franchise is expected to continue due to intense competition from multiple drugs including Epclusa whose label was expanded to include HIV co-infection in August. Moreover, the HIV business continues to face competitive pressure. Recent launches by other companies in the same space are expected to further impact the Sustiva franchise. The Zacks Consensus Estimate for Hepatitis C franchise sales is pegged at $108 million this quarter, down 71.5% from year ago quarter.
The company is developing its key drug, Opdivo as monotherapy as well as combination therapy for several tumor types in multiple studies, with two label expansion applications under review in the United States. We expect investor focus on updates related to Opdivo in the conference call.
Why a Likely Positive Surprise?
Our proven model indicates that Bristol-Myers is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate (earnings of 77 cents) and the Zacks Consensus Estimate (earnings of 76 cents), stands at +0.79%. This is a leading indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Bristol-Myers currently has a Zacks Rank #3. The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat.
Conversely, we caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Bristol-Myers Squibb Company Price and EPS Surprise
Here are some biotech stocks that you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Celgene Corp. is scheduled to release its results on Oct 26. The company has an Earnings ESP of +0.08% and a Zacks Rank #3.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?
We expect Bristol-Myers Squibb Company (BMY - Free Report) to beat expectations when it reports third-quarter 2017 results on Oct 26, before the market opens.
Year to date, Bristol-Myers’ shares have increased 10.2% while the industry has recorded an increase of 20.5%.
Bristol-Myers’ track record has been positive so far. The company delivered positive earnings surprise in three of the last four quarters and missed expectations in one. The average positive earnings surprise in the last four quarters is 7.99%. In the last reported quarter, Bristol-Myers came up with a positive surprise of 1.37%.
Let’s see how things are shaping up for this quarter.
Factors at Play
Bristol-Myers’ high-profile immuno-oncology drug, Opdivo is expected to be the primary sales driver in the third quarter. The drug is already approved in multiple cancer indications. During this quarter, the FDA approved the drug for two additional indications – hepatocellular carcinoma and metastatic colorectal cancer – in patients who have received prior treatment. Although, these label expansions are not expected to have much impact on the top line, these when combined with the two label expansions in the second quarter will certainly boost sales.
Although the second quarter saw some stability in the second-line lung cancer setting, FDA’s approval of Merck’s (MRK - Free Report) Keytruda in May for the first-line treatment of metastatic nonsquamous NSCLC will increase competition and may impact sales unfavorably. The Zacks Consensus Estimates indicates the drug sales to increase 31% from the year-ago quarter to $1.2 billion.
In July, the FDA also approved the label expansion of Yervoy injection in pediatric patients 12 years of age and older with unresectable or metastatic melanoma. The Zacks Consensus Estimate for the drug this quarter is $323 million.
Meanwhile, rheumatoid arthritis drug, Orencia, received approval for treating psoriatic arthritis in the United States as well as in Europe in July. Moreover, in June, Bristol-Myers announced the availability of subcutaneous administration option for Orencia in patients with moderately to severely active polyarticular juvenile idiopathic arthritis. The label expansion and new administration option is expected to fuel growth of the drug. The drug, which registered growth of 10% in the previous quarter, is expected to generate sales of $635 million this quarter, per the Zacks Consensus Estimate.
On the other hand, the decline in the Hepatitis C franchise is expected to continue due to intense competition from multiple drugs including Epclusa whose label was expanded to include HIV co-infection in August. Moreover, the HIV business continues to face competitive pressure. Recent launches by other companies in the same space are expected to further impact the Sustiva franchise. The Zacks Consensus Estimate for Hepatitis C franchise sales is pegged at $108 million this quarter, down 71.5% from year ago quarter.
The company is developing its key drug, Opdivo as monotherapy as well as combination therapy for several tumor types in multiple studies, with two label expansion applications under review in the United States. We expect investor focus on updates related to Opdivo in the conference call.
Why a Likely Positive Surprise?
Our proven model indicates that Bristol-Myers is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate (earnings of 77 cents) and the Zacks Consensus Estimate (earnings of 76 cents), stands at +0.79%. This is a leading indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Bristol-Myers currently has a Zacks Rank #3. The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat.
Conversely, we caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Bristol-Myers Squibb Company Price and EPS Surprise
Bristol-Myers Squibb Company Price and EPS Surprise | Bristol-Myers Squibb Company Quote
Other Stocks That Warrant a Look
Here are some biotech stocks that you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Clovis Oncology, Inc. is expected to release its results on Nov 2. The company has an Earnings ESP of +2.01% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Celgene Corp. is scheduled to release its results on Oct 26. The company has an Earnings ESP of +0.08% and a Zacks Rank #3.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>